Spondyloarthritis

Article

Ode to Our Editor: Honoring Dr. Jack Cush

Christopher Ritchlin, MD, MPH Artie Kavanaugh, MD Nov 06, 2026

For someone who has spent so much of his career recognizing the work of others, it is fitting that Dr. John J. “Jack” Cush should have his own moment in the spotlight.

AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity @RheumNow @APLAR2026 https://t.co/GDFSwt2IOm

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

https://x.com/drpnash/status/2116402903040897383/photo/1

Dr. Poddubny on AI & machine learning in SpA AI has enabled the analysis of large data sets offering a support for clinical decision-making. Future directions? Making scans faster leading to rapid analysis Challenge: access to large, high quality data @RheumNow #APLAR2026 https://t.co/UhdjSRXtOv

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz

T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed @RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok

https://x.com/drpnash/status/2116405424090153127/photo/1

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Ass…

Oswestry Disability Index in axSpA (n=107, India): a patient-reported, low-cost, quick tool that tracked closely with BASDAI (r=0.77), BASFI (r=0.80) and ASDAS-CRP (r=0.79). Could help where rheumatologists are scarce. P#478 #APLAR26 @RheumNow https://t.co/teoMtnM3Gl

https://x.com/JihaRheum/status/2115985118280224811/photo/1

Deep learning DIXON MRI of SI joints (n=76, suspected axSpA): 5:24 min vs 19:49 for standard MRI (>70% faster). AUC 0.86 vs 0.87; specificity 98% vs 89%, but sensitivity 74% vs 84%. Faster, more accessible screening, with a sensitivity trade-off. #APLAR26 @RheumNow https://t.co/YUTQwcDmsz

A positive SI joint MRI alone is not specific for axSpA: ASAS MRI-positive in 23.4% of healthy volunteers, 12.5% of runners and 57.1% of postpartum back pain, vs 91.5% of axSpA. Without clinical context, overdiagnosis is a risk. AYR session #APLAR26 @RheumNow https://t.co/U3wFOm01B4

Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th! Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more. Visit https://t.co/ofGKCCNQnE for the latest coverage. #ACR26 #Rheumatology https://t.co/5p5UxMLu51

Home | RheumNow

High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. (CDC https://t.co/wnPdEueb4N

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c

Market info: Ankylosing Spondylitis market size in USA estimated at $3.3 billion USD in 2020 & is expected to increase 8.36% annually from 2019–2032. US prevalence of AS in 2020 was 1,300,971 cases https://t.co/EAginmKFF9 https://t.co/2Ye4Gk1awT

Ankylosing Spondylitis Market in the US to Grow from USD 3,366.93 Million at a …

Article

‘Tis the Season for Vaccination

Eric Dein, MD Oct 19, 2026

As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic

? value of FamHx in Rheum evals? My bias is that few Dz are heritable - #Ank Spondylitis, #gout, DIP Osteoarthritis! But literature says there's high heritability for SLE, RA, systemic sclerosis, Sjögren's, & autoimmune endocrinopathies. WHAT do you think? https://t.co/WGyQqpY1qX

Article

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD Oct 09, 2026

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.

J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/gZuuQ4jcEf

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 i…

Article

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD Oct 02, 2026

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/2Tdg96rWFX

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 i…

The Friday RheumNow podcast has dropped! In this week's episode, "Rheumatology Pay Up," Dr. Jack Cush covers: • Rheumatology physician pay rose 10.4% year-over-year • New data on colchicine and tofacitinib in knee OA • What a new study tells us about earlier axSpA diagnosis https://t.co/oXsNruWnc2

Earlier Dx of axSpA is assoc w/ lower long-term spinal structural damage. Swiss study compared xray outcomes betw 138 early (<2yrs) & 238 established axSpA pts w/ 11.5 yrs F/U. Differences became evident 10-15 yrs after Dx. https://t.co/E9oR37CEiD https://t.co/7FiaqJIRRC

Early diagnosis of axial spondyloarthritis is associated with less long‐term sp…

Article

Rheumatology Pay Up (9.25.2026)

Jack Cush, MD Sep 25, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

It’s almost time. 🔥 Registration for RheumNow Live 2027 opens OCTOBER 1. Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice. 📅 Jan 30–31, 2027 📍 Dallas + Online https://t.co/Ju0zzYX8Tl

Discussing Weight Loss: 3 Minute Script Dr. Jack Cush's 3 Minute Script as discussed in his Introducing Weight Loss video. https://t.co/JRWAPc5if5 https://t.co/jI65VzTIfs